Du är här

2016-02-02

Sanofi : Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

- Building on the company's successful history in developing vaccines against
similar viruses, most recently the introduction of Dengvaxia®against dengue,
Sanofi Pasteur is launching a Zika vaccine project -

Lyon, France - February 2, 2016 -
Sanofi Pasteur, the vaccines division ofSanofi, announced today that it has
launched a vaccine research and development project targeting the prevention
of Zika virus infection and disease.

Sanofi Pasteur leads the vaccine field for viruses in the same family as Zika
virus (ZIKV), with licensed vaccines against Yellow Fever, Japanese
Encephalitis and, most recently, Dengue. Importantly, Sanofi Pasteur's
expertise and established R&D and industrial infrastructure for the newly
licensed vaccine for dengue, Dengvaxia®, can be rapidly leveraged to help
understand the spread of ZIKV and potentially speed identification of a
vaccine candidate for further clinical development.

"Our invaluable collaborations with scientific and public health experts, both
globally and in the regions affected by the outbreaks of ZIKV, together with
the mobilization of our best experts will expedite efforts to research and
develop a vaccine for this disease,"
said Dr. John Shiver, Global Head of R&D, Sanofi Pasteur.

The ZIKV is closely related to Dengue; it belongs to the sameFlavivirus
genus, is spread by the same species of mosquito and has a similar acute
clinical presentation. Common symptoms caused by a Zika infection include
fever, rash, joint swelling, conjunctivitis and headaches. However, there is
a growing body of evidence linking Zika infection in pregnant women with an
increased risk of a severe congenital complication at birth called
microcephaly. Normally a rare condition, microcephaly results in an
abnormally small head impairing brain development.

"Sanofi Pasteur is responding to the global call to action to develop a Zika
vaccine given the disease's rapid spread and possible medical complications,"
says Dr. Nicholas Jackson, Global Head of Research for Sanofi Pasteur who will
be driving the new ZIKV vaccine project."In addition to the serious
possibility of congenital complications associated
with Zika, investigations are also underway to assess another reported
connection between Zika and a dangerous neurological disorder".

Until recently, ZIKV was considered a rare and seemingly benign virus. However
in May 2015, the Pan American Health Organization (PAHO) issued an alert
regarding the first confirmed ZIKV infection in Brazil, and since then it has
spread across the Americas. In the United States, authorities have reported a
locally transmitted case of Zika in Puerto Rico, with reports of cases in
continental United States in returning travelers.

At a briefing session during the 138th Executive Board of the World Health
Organization (WHO), the WHO Director General, Dr. Margaret Chan, stated that
the WHO is deeply concerned about ZIKV for four main reasons:

* the possible association of infection with birth malformations and
neurological syndromes;
* the potential for further international spread given the wide geographical
distribution of the mosquito vector;
* the lack of population immunity in newly affected areas;
* absence of vaccines, specific treatments, and rapid diagnostic tests.

In addition, the Centers for Disease Control and Prevention (CDC) have issued
travel recommendations for pregnant women to post-pone travel to countries in
Latin America and the Caribbean where ZIKV transmission is ongoing.

Presently there is no vaccine or specific treatment for Zika. Vector control
remains an important means of potentially controlling the mosquitoes
responsible for spreading Zika.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT:SAN) and in New York (NYSE:SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion
doses of vaccine each year, making it possible to immunize more than 500
million people across the globe. A world leader in the vaccine industry,
Sanofi Pasteur offers a broad range of vaccines protecting against 20
infectious diseases. The company's heritage, to create vaccines that protect
life, dates back more than a century. Sanofi Pasteur is the largest company
entirely dedicated to vaccines. Every day, the company invests more than EUR
1 million in research and development. Sanofi Pasteur is committed to
supporting the global public health community fight preventable disease and
supports public private partnerships that leverage diverse capabilities to
expeditiously respond to potential epidemics. For more information, please
visit:www.sanofipasteur.comorwww.sanofipasteur.us

Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.

---------------------------------------
Contacts:

-------------------------------------------------------------------
| Global Media Relations U.S. /Country Media Relations |
| Alain Bernal Susan Watkins |
| T. +33-4-37-37-50-38 T. +570-957-2563 |
| alain.bernal@sanofipasteur.com susan.watkins@sanofipasteur.com |
| www.sanofipasteur.com www.sanofipasteur.us |
-------------------------------------------------------------------
Investor Relations

Sébastien Martel
T. + 33 1 53 77 45 45
ir@sanofi.com

Press release (PDF)
http://hugin.info/152918/R/1982826/726583.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#1982826

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.